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Abstract
Background: Lifestyle factors, such as an unbalanced diet and lack of physical activity, may affect the prevalence
of metabolic syndrome (MetS) in schizophrenic patients. The aim of this study was to compare the MetS
prevalence between inpatients and outpatients among schizophrenic population in Japan.
Methods: We recruited inpatients (n = 759) and outpatients (n = 427) with a Diagnostic and Statistical Manual of
Mental Disorders, fourth edition (DSM-IV) diagnosis of schizophrenia or schizoaffective disorder from 7 psychiatric
hospitals using a cross-sectional design. MetS prevalence was assessed using three different definitions, including
the adapted National Cholesterol Education Program Adult Treatment Panel (ATP III-A).
Results: The overall MetS prevalences based on the ATP III-A definition were 15.8% in inpatients and 48.1% in
outpatients. In a logistic regression model with age and body mass index as covariates, being a schizophrenic
outpatient, compared to being a schizophrenic inpatient, was a significant independent factor (odds ratio = 3.66
for males, 2.48 for females) in the development of MetS under the ATP III-A definition. The difference in MetS
prevalence between inpatients and outpatients was observed for all age groups in males and for females over
40 years of age.
Conclusions: Outpatients with schizophrenia or schizoaffective disorder in Japan had a high prevalence of MetS
compared to inpatients. MetS in schizophrenic outpatients should be carefully monitored to minimize the risks.
A change of lifestyle might improve MetS in schizophrenic patients.
Introduction
A high prevalence of metabolic syndrome (MetS) has
been reported among schizophrenic patients [1-3]. MetS
has been related to an increased risk for cardiovascular
diseases [4,5], diabetes [6] and mortality [7] and is
defined as a cluster of metabolic disturbances including
abdominal obesity, atherogenic dyslipidemia, hyperten-
sion and hyperglycemia [8].
Commonly used definitions for MetS are the National
Cholesterol Education Program Adult Treatment Panel
(NCEP ATP III) MetS definition [7] and the adapted NCEP
ATP III (ATP III-A) definition, proposed by the American
Heart Association (AHA) following the American Diabetes
Association’s( A D A ’s) lowering of the threshold for
impaired fasting glucose to 100 mg/dl [9]. Because abdom-
inal obesity is widely recognized as a measure of metabolic
abnormality, the International Diabetes Federation (IDF)
established a definition that stressed the importance of
waist circumference [10]. However, the small physique of
the Asian population made it difficult to use the same waist
circumference criterion determined for those of European
descent [11]. Therefore, modified criteria for waist circum-
ference (90 cm for males and 80 cm for females) have been
proposed for Asians in the ATP III-A [12] and IDF [13]
definitions. In addition, a definition established by the
Japan Society for the Study of Obesity (JASSO) [14] was
also used in this study. Based on an area of 100 cm
2 of
intra-abdominal fat, the cut-off value for waist circumfer-
ence is 85 cm for males and 90 cm for females under the
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of the Criteria for Metabolic Syndrome established the
JASSO definition, there has been controversy concerning
the effective cut-off value for waist circumference [16].
Lifestyle factors, such as an unbalanced diet and lack
of physical activity, could cause MetS. Patients with
schizophrenia are at risk for developing obesity due to
poor dietary habits or limited physical activity because
of the negative symptoms of schizophrenia. In addition,
Japan has the highest number of psychiatric beds per
100,000 people in the world [17]. The mean length of
hospital stay is about 1.5 years [18]. Because schizophre-
nic inpatients have received controlled meals and occu-
pational therapy, the lifestyles of schizophrenic patients
may be different from those of outpatients.
To clarify the effect of environmental factors on MetS in
the schizophrenic population, we compared the prevalence
of MetS based on the type of care (inpatient vs outpatient).
To the best of our knowledge, this is the first study carried
out in the schizophrenic population.
Methods
Participants
This study was conducted between January 2007 and
December 2008. Subjects were 759 inpatients (355 males
and 404 females) and 427 outpatients (215 males and 212
females) from 7 psychiatric hospitals in Japan who were
diagnosed with either schizophrenia or schizoaffective dis-
order based on the Diagnostic and Statistical Manual of
Mental Disorders, fourth edition (DSM-IV) diagnosis. The
diagnoses of the patients were recorded based on their
medical charts. All subjects were previously instructed to
fast from midnight prior to the assessment day. The data
collection for this study was approved by the Ethics Com-
mittee of the Hirosaki University School of Medicine and
all subjects provided written informed consent before par-
ticipating in this study. The characteristics of the study
population have been reported previously [19]. In this
study, we reanalyzed the subjects based on the type of care
(inpatient vs outpatient).
Measurements
The subjects’ demographic data (age and sex) were
obtained from their medical records. The height and
weight of the subjects were measured, and body mass
index (BMI) was calculated. Waist circumference to the
nearest 0.1 cm was measured at the umbilical level with
the subject in a standing position by a technician in the
morning. Trained technicians measured blood pressure
(BP) using standard mercury sphygmomanometers on the
right arm of seated participants after a 5 min rest period.
High-density lipoprotein (HDL) cholesterol, triglycerides
and fasting blood glucose were also measured using stan-
dard analytical techniques. The presence of MetS was
determined based on the definitions given by the ATP
III-A for Asians, the recent IDF for Japanese populations
and the JASSO (Table 1).
Statistical analysis
Descriptive statistics were computed to describe the
demographic and clinical variables. In order to compare
the main demographic and clinical characteristics
between groups, the unpaired Student’stt e s tw a sp e r -
formed to analyze continuous variables, and a c
2 test or
Fisher’s exact test was performed to analyze categorical
variables. After adjusting for confounding factors (age
and BMI), a multivariate logistic regression analysis was
performed to assess the influence of schizophrenia as a
risk factor for MetS. A value of P < 0.05 was considered
significant. The data were analyzed using SPSS software
for Windows (Version 12.0).
Results
Demographic and clinical characteristics
Demographic and clinical characteristics of the study
population are shown in Table 2. Schizophrenic outpati-
ents were significantly younger and taller, and had
higher weight, BMI, waist circumference, systolic BP,
diastolic BP, triglyceride and fasting blood glucose than
schizophrenic inpatients.
MetS and criteria prevalence among subjects
The data in Table 3 shows significant patterns of MetS cri-
teria prevalence by type of care (inpatients vs outpatients).
The unadjusted MetS prevalences among schizophrenic
outpatients (inpatients) using the ATP III-A, IDF and
JASSO definitions were 48.1% (15.8%), 44.1% (14.7%) and
33.2% (9.1%), respectively. The prevalence of all the cri-
teria is significantly higher in the outpatient group than in
the inpatient group. Among schizophrenic inpatients, an
association between gender and MetS prevalence was sig-
nificant based on the JASSO and IDF definitions (JASSO:
c
2 = 16.03, df = 1, P < 0.001, IDF: c
2 =4 . 0 4 ,d f=1 ,P <
0.05) but was not significant based on the ATP III-A defi-
nition (c
2 = 1.49, df = 1, P = 0.22). Schizophrenic outpati-
ents showed an association between gender and MetS
prevalence that was significant based on the JASSO and
ATP III-A definitions (JASSO: c
2 = 31.19, df = 1, P <
0.001, ATP III-A: c
2 = 9.94, df = 1, P < 0.01), but was not
significant based on the IDF definition (c
2 = 3.60, df = 1,
P = 0.058).
Male inpatients with schizophrenia showed higher
prevalences of criteria for waist circumference (JASSO:
c
2 = 15.65, df = 1, P < 0.001), BP (ATP III-A, IDF,
JASSO: c
2 =1 2 . 9 8 ,d f=1 ,P <0 . 0 0 1 )a n dT Ga n d / o r
HDL (JASSO: c
2 = 21.71, df = 1, P < 0.001) than female
inpatients. However, more female inpatients with schizo-
phrenia met the criteria for waist circumference (ATP
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2 = 88.17, df = 1, P < 0.001) than male
inpatients. No significant differences were seen in HDL
(ATP III-A, IDF: c
2 =2 . 6 9 ,d f=1 ,P = 0.10), TG (ATP
III-A, IDF: c
2 =2 . 7 5 ,d f=1 ,P = 0.097) and fasting
plasma glucose levels (ATP III-A, IDF: c
2 = 3.96, df = 1,
P = 0.529, JASSO: c
2 = 0.10, df = 1, P = 0.751).
Male outpatients with schizophrenia showed higher
prevalences of criteria for waist circumference (JASSO:
c
2 = 39.46, df = 1, P < 0.001), BP (ATP III-A, IDF,
JASSO: c
2 = 13.57, df = 1, P < 0.001), TG (ATP III-A,
IDF: c
2 = 15.53, df = 1, P <0 . 0 0 1 ) ,T Ga n d / o rH D L
(JASSO: c
2 = 23.80, df = 1, P < 0.001) and fasting
plasma glucose levels (ATP III-A, IDF: c
2 = 4.48, df = 1,
P < 0.05) than female outpatients. No significant differ-
ence was seen in waist circumference (ATP III-A, IDF:
c
2 = 1.22, df = 1, P =0 . 2 7 0 ) ,H D L( A T PI I I - A ,I D F :
c
2 =1 . 4 9 ,d f=1 ,P = 0.22) and fasting plasma glucose
levels (JASSO: c
2 = 0.46, df = 1, P = 0.50)
The effect of type of care on the odds ratio for MetS
To examine the independent effect of type of care for
schizophrenia on the odds ratio of for MetS, two logistic
regression models were developed with MetS status as
the binary dependent variable (Table 4). Due to the dif-
ferences in the criteria for MetS by gender, these models
were constructed in a gender-specific manner. In model
1, the odds ratios of having MetS were greater for male
schizophrenic outpatients (ATP III-A: odds ratio = 7.57,
95% CI = 4.83 to 11.86, P < 0.001, IDF: odds ratio = 6.72,
95% CI = 4.19 to 10.78, P < 0.001, JASSO: odds ratio =
6.07, 95% CI = 3.80 to 9.71, P < 0.001), and female schi-
zophrenic outpatients (ATP III-A: odds ratio = 4.24, 95%
CI = 2.70 to 6.67, P < 0.001, IDF: odds ratio = 3.95, 95%
CI = 2.50 to 6.24, P < 0.001, JASSO: odds ratio = 5.66,
95% CI = 2.92 to 10.94, P <0 . 0 0 1 )w h e na n a l y z e dw i t h
illness and age as covariates. In the second model, the
odds ratios for both male and female schizophrenic
outpatients were also statistically significant when BMI
was added as a covariate.
Age-specific prevalence of metabolic syndrome
Figure 1 shows the age-specific prevalences of MetS
(ATP III-A) for both genders. In all age groups, MetS
prevalence for male schizophrenic outpatients was
greater than inpatients. For female schizophrenic outpa-
tients, the prevalence was statistically higher in the over
40 age group. The age-specific prevalences of MetS
using the IDF and JASSO definitions showed similar
tendencies (data not shown).
Discussion
Control of diet and physical activity may affect the
development of MetS. The services provided for patients
differ based on the type of care, such as hospital or
community-based care. The type of care could be a
large environmental factor. However, there have been
few studies that compare the prevalence of MetS among
patients receiving different types of care. In this study,
we reported the prevalence of MetS in inpatients and
outpatients diagnosed with schizophrenia. Compared to
inpatients, outpatients were found to be at a higher risk
of developing MetS.
Previous studies of inpatients with schizophrenia have
reported that the prevalence of MetS ranged from 27 to
29% using the ATP III definition [20,21]. With the same
definition, the prevalence of MetS among outpatients
with schizophrenia ranged from 25% to 35% [3,22].
Although there have been some reports of the preva-
lence of MetS in patients undergoing inpatients or out-
patient care, we could not compare the prevalence of
MetS because the patients in these studies were treated
under different systems of medical care.
In this study, outpatients with schizophrenia were
found to be at a higher risk of developing MetS than
Table 1 Definitions of metabolic syndrome
ATP III-A
a IDF
b JASSO
c
Waist circumference (cm) Male ≥ 90, female ≥ 80 Male ≥ 90, female ≥ 80 Male ≥ 85, female ≥ 90
Blood pressure (mmHg)
d ≥ 130/85 ≥ 130/85 ≥ 130/85
HDL (mg/dl)
e Male < 40, female < 50 Male < 40, female < 50 < 40
TG (mg/dl)
e ≥ 150 ≥ 150 ≥ 150
Glucose (mg/dl)
f ≥ 100 ≥ 100 ≥ 110
aMetabolic syndrome if three of five criteria are met.
bMetabolic syndrome if waist circumference plus two criteria are met.
cMetabolic syndrome if waist circumference plus two of the following criteria are met: high blood pressure, reduced high-density lipoprotein (HDL) and/or raised
triglyceride (TG), raised fasting hyperglycemia.
dOr specific treatment of previously diagnosed hypertension.
eOr specific treatment for this lipid abnormality.
fOr specific treatment with insulin or hypoglycemic medication.
ATP III-A = Adapted National Cholesterol Education Program Adult Treatment Panel; IDF = International Diabetes Federation; JASSO = Japan Society for the Study
of Obesity.
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Page 3 of 8Table 2 Demographic and clinical characteristics of the subjects
Total Male Female
Inpatients, (n =
759)
Outpatients, (n =
427)
P
value
Inpatients, (n =
355)
Outpatients, (n =
215)
P
value
Inpatients, (n =
404)
Outpatients, (n =
212)
P
value
Age (years) 59.9 ± 12.9 45.6 ± 13.6 < 0.001 58.3 ± 13.1 45.2 ± 13.5 < 0.001 61.4 ± 12.5 46.0 ± 13.7 < 0.001
Height (cm) 158.3 ± 9.8 162.6 ± 9.9 < 0.001 165.1 ± 7.2 168.5 ± 6.6 < 0.001 152.3 ± 7.7 156.4 ± 8.9 < 0.001
Weight (kg) 55.7 ± 11.8 69.3 ± 14.4 < 0.001 60.8 ± 11.6 75.2 ± 11.9 < 0.001 51.2 ± 10.1 63.2 ± 14.2 < 0.001
BMI (kg/m
2) 22.1 ± 4.0 26.5 ± 11.4 < 0.001 22.2 ± 4.0 26.5 ± 3.9 < 0.001 22.0 ± 4.0 26.6 ± 15.7 < 0.001
Waist circumference
(cm)
82.9 ± 10.7 90.3 ± 12.4 < 0.001 82.9 ± 10.3 92.8 ± 10.7 < 0.001 83.0 ± 11.0 87.5 ± 13.4 < 0.05
Systolic BP (mmHg) 117.8 ± 16.1 127.9 ± 20.0 < 0.001 119.6 ± 16.5 131.4 ± 19.8 < 0.001 116.2 ± 15.5 124.4 ± 18.8 < 0.001
Diastolic BP (mmHg) 73.3 ± 11.6 78.7 ± 13.1 < 0.001 75.2 ± 12.1 80.9 ± 12.9 < 0.001 71.7 ± 10.8 76.5 ± 13.0 < 0.001
HDL-C (mg/dl) 55.0 ± 15.3 53.8 ± 16.1 NS 49.8 ± 12.5 49.3 ± 15.3 NS 59.5 ± 16.1 58.4 ± 15.6 NS
Triglyceride (mg/dl) 96.7 ± 56.5 167.8 ± 126.1 < 0.001 99.1 ± 63.6 202.3 ± 148.4 < 0.001 94.6 ± 49.5 133.2 ± 86.2 < 0.001
Fasting glucose (mg/dl) 90.6 ± 18.6 115.7 ± 52.2 < 0.001 91.0 ± 20.9 118.1 ± 53.2 < 0.001 90.3 ± 16.3 113.3 ± 51.2 < 0.001
Data are expressed as mean ± SD. These data were analyzed using Student’s t test between the reference group and the schizophrenic patients.
BP = blood pressure; BMI = body mass index; HDL-C = high-density lipoprotein cholesterol; NS = not significant.
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8Table 3 Prevalence of metabolic syndrome (MetS) and its criteria among subjects
All Male Female
Inpatients Outpatients P value Inpatients Outpatients P value Inpatients Outpatients P value
MetS prevalence:
ATP III-A 15.8 48.1 < 0.001 14.1 55.8 < 0.001 17.3 40.6 < 0.001
IDF 14.7 44.1 < 0.001 11.9 48.6 < 0.001 17.1 39.4 < 0.001
JASSO 9.1 33.2 < 0.001 13.6 45.8 < 0.001 5.1 20.2 < 0.001
MetS criteria prevalence:
Waist circumference
Male ≥ 90 cm, female ≥ 80 cm 46.2 64.2 < 0.001 27.8 61.7 < 0.001 62.4 66.8 NS
Male ≥ 85 cm, female ≥ 90 cm 34.9 59.0 < 0.001 42.3 73.8 < 0.001 28.4 43.8 < 0.001
BP (≥ 130/85 mmHg) 30.7 46.7 < 0.001 37.2 55.5 < 0.001 25.1 37.5 < 0.01
HDL (male < 40 mg/dl, female < 50 mg/dl) 25.5 31.8 < 0.05 22.7 28.9 NS 28.0 34.8 NS
Triglyceride (≥ 150 mg/dl) 11.2 40.6 < 0.001 13.2 50.2 < 0.001 9.4 31.0 < 0.001
HDL (< 40 mg/dl) and TG (≥ 150 mg/dl) 20.8 46.1 < 0.001 28.2 58.1 < 0.001 14.4 34.0 < 0.001
Glucose (≥ 100 mg/dl) 17.5 50.9 < 0.001 16.6 56.0 < 0.001 18.4 45.5 < 0.001
Glucose (≥ 110 mg/dl) 9.5 35.3 < 0.001 9.9 36.8 < 0.001 9.2 33.7 < 0.001
All prevalences are expressed as a percentage (%) and were analyzed using the c
2 test comparing the reference group and the schizophrenic patients.
ATP III-A = Adapted National Cholesterol Education Program Adult Treatment Panel; BP = blood pressure; IDF = International Diabetes Federation; JASSO = Japan Society for the Study of Obesity; HDL = high-density
lipoprotein; NS = not significant.
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8inpatients with schizophrenia. Using the ATP III-A and
JASSO definitions, male outpatients have a higher preva-
lence of MetS than female outpatients. Among inpati-
ents with schizophrenia, female inpatients showed a
higher prevalence of MetS than male inpatients using
the IDF definition, while male inpatients showed a
higher prevalence of MetS than female inpatients using
the JASSO definition.
The prevalence rates of MetS reported in previous stu-
dies have varied considerably due to the different defini-
tions of the syndrome used in each study. In this study,
the prevalence rate of MetS (5.1%) among female schizo-
phrenic inpatients using the JASSO definition seems to be
extremely low compared to those obtained using the ATP
III-A (17.3%) and IDF (17.1%) definitions. This difference
may be due to the influence of increasing the waist cir-
cumference criterion to 90 cm [14]. The specific values of
waist circumference used to assess MetS in the Japanese
population have changed in the IDF definition: the current
specific values for Japanese are 90 cm for men and 80 cm
for women [13], as in the ATP III-A definition. Though
the effective cut-off value for waist circumference is still
controversial, the ATP III-A or IDF criteria may be suita-
ble for making international comparisons because of the
availability of data in several different ethnic groups.
As mentioned earlier, no significant difference in MetS
prevalence between inpatients and outpatients was
observed in females aged 39 years and younger. The
results using the IDF and JASSO definitions were simi-
lar. One possible explanation is that this study failed to
find a difference in MetS prevalence in females aged 39
years and younger due to smaller sample sizes. Another
possible explanation is that the later age at onset of
female schizophrenic patients compared to schizophre-
nic male patients [23,24] might cause differences in
duration of treatment between genders.
The reason for this increased prevalence among outpati-
ents has not been entirely elucidated. However, schizophre-
nic inpatients have received controlled diets and
occupational therapy. Schizophrenic inpatients in Japan
typically have long hospital stays, and the above-mentioned
treatment might influence the lower prevalences of MetS
in this study. Previous studies [25,26] have suggested that
long-term programs that incorporate nutrition, exercise,
and behavioral interventions can prevent weight gain
among schizophrenic patients. An effective intervention
program could reduce the high risk for developing MetS
among male outpatients.
The current study also has some limitations. Firstly, it
was a cross-sectional study. It is necessary to carry out a
follow-up survey to clarify the reason for not finding a
difference in the MetS prevalence between inpatients
and outpatients among female subjects aged 39 and
younger. Secondly, patient recruitment was restricted to
Table 4 Logistic regression models of metabolic syndrome (MetS) status in subjects
Model 1 Model 2
Covariate OR (95% CI) P value Covariate OR (95% CI) P value
Male:
ATP III-A Outpatients 7.569 (4.829 to 11.863) < 0.001 Outpatients 3.664 (2.187 to 6.139) < 0.001
Age 1.000 (0.985 to 1.015) NS Age 1.015 (0.998 to 1.036) NS
BMI 1.479 (1.365 to 1.602) < 0.001
IDF Outpatients 6.717 (4.188 to 10.7765) < 0.001 Outpatients 2.506 (1.397 to 4.496) < 0.01
Age 0.998 (0.983 to 1.014) NS Age 1.018 (0.996 to 1.040) NS
BMI 1.677 (1.517 to 1.855) < 0.001
JASSO Outpatients 6.071 (3.795 to 9.711) < 0.001 Outpatients 2.599 (1.505 to 4.488) < 0.01
Age 1.011 (0.995 to 1.027) NS Age 1.034 (1.014 to 1.055) < 0.01
BMI 1.467 (1.354 to 1.589) < 0.001
Female:
ATP III-A Outpatients 4.243 (2.699 to 6.671) < 0.001 Outpatients 2.477 (1.474 to 4.161) < 0.01
Age 1.017 (1.002 to 1.032) < 0.05 Age 1.032 (1.013 to 1.050) < 0.01
BMI 1.332 (1.253 to 1.416) < 0.001
IDF Outpatients 3.952 (2.497 to 6.254) < 0.001 Outpatients 2.842 (1.738 to 4.647) < 0.001
Age 1.015 (1.000 to 1.030) NS Age 1.021 (1.004 to 1.038) < 0.05
BMI 1.143 (1.090 to 1.198) < 0.001
JASSO Outpatients 5.655 (2.923 to 10.940) < 0.001 Outpatients 4.137 (2.047 to 8.361) < 0.001
Age 1.010 (0.989 to 1.031) NS Age 1.012 (0.990 to 1.035) NS
BMI 1.089 (1.027 to 1.154) < 0.01
ATP III-A = Adapted National Cholesterol Education Program Adult Treatment Panel; BMI = body mass index; IDF = International Diabetes Federation; JASSO =
Japan Society for the Study of Obesity; OR = odds ratio; NS = not significant.
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Page 6 of 8hospitals where outpatients and inpatients presented for
a review of their health problems. No other population
groups were included, such as children, adolescents or
unmedicated patients. Thirdly, some patients, who were
diagnosed with schizophrenia may have had metabolic
disturbances prior the use of antipsychotics [27]. Lastly,
some parameters that may contribute to MetS were not
included in this study, such as dietary habits, physical
activity levels, duration of illness and treatment, length
of the current stay in hospital among inpatients, schizo-
phrenic symptoms and medications. Antipsychotic med-
ications may be especially important factors. The use of
first-generation or second-generation antipsychotics
might confound the results. Stratification by drug use is
needed in further studies.
Conclusions
This study has shown that the prevalence of MetS in
Japanese outpatients with schizophrenic and schizoaffec-
tive disorders was higher than in inpatients and was
considerably higher in male outpatients. Therefore,
metabolic abnormalities in schizophrenic patients should
be monitored carefully and treated in an appropriate
manner.
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